Petosemtamab + Chemotherapy for Colorectal Cancer

This trial tests a new treatment for individuals with colorectal cancer that has returned after treatment, cannot be surgically removed, or has spread to other parts of the body. Researchers aim to evaluate the effectiveness of an experimental drug, petosemtamab, when combined with chemotherapy compared to standard treatments. Participants will receive either petosemtamab with chemotherapy or standard treatments with chemotherapy. This trial may suit those with confirmed advanced colorectal adenocarcinoma who have already tried one type of treatment. Participants will attend regular clinic visits for tests and monitoring to ensure safety and effectiveness. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants access to potentially groundbreaking treatment.

A previous study found that petosemtamab was generally well-tolerated by patients. Most side effects were mild to moderate, such as fatigue or nausea. Serious side effects were rare, indicating that while some people felt uncomfortable, few experienced severe issues.

Cetuximab and bevacizumab, used in this trial for comparison, have received FDA approval for other uses, indicating their safety is well-known. Common side effects of these drugs include skin reactions and high blood pressure, while serious side effects like allergic reactions occur less frequently.

Petosemtamab is unique because it introduces a new active ingredient specifically designed to target colorectal cancer cells. Unlike standard treatments like 5-FU or irinotecan, which attack rapidly dividing cells in general, petosemtamab is a monoclonal antibody that zeroes in on specific proteins found on cancer cells, potentially reducing side effects by sparing healthy cells. Researchers are excited about petosemtamab because it could offer a more targeted approach, potentially improving effectiveness and safety compared to current chemotherapy regimens.

This trial will compare the effectiveness of Petosemtamab combined with chemotherapy to other treatment options. Studies have shown that using Petosemtamab with chemotherapy can help treat colorectal cancer. Recent research found that this combination reduced tumor size in 67% of patients who had already received treatment. Another study showed that when Petosemtamab was used as the first treatment, 75% of patients responded positively. These findings suggest that Petosemtamab could be promising for treating colorectal cancer, especially when used with chemotherapy. Meanwhile, the trial's other arm will evaluate the use of Cetuximab or Bevacizumab with chemotherapy, which are established treatments for colorectal cancer.⁶⁷⁸⁹¹⁰